This study retrospectively evaluates one institution's experience using reteplase
as the thrombolytic drug alone, and with the addition of the platelet inhibiting drug reopro, in more difficult cases.
Results of the Early Reteplase
Thrombolysis in Myocardial Infarction-19 (ER TIMI-19) trial, reported by Dr.
The study population involves a broad range of patients presenting with STEMI, including those treated with a range of thrombolytic regimens (streptokinase, r-t-PA, reteplase
, tenecteplase), primary percutaneous coronary intervention (PCI) and those not eligible for reperfusion therapy (e.
One of the new options, half-dose reteplase
plus heparin and a half dose of abciximab, an antiplatelet drug, looked especially good for younger patients and those with larger infarctions, Dr.
ExTRACT is a 21,000 patient, multi-national and indication-seeking trial, investigating the efficacy and safety of LOVENOX(R) compared to UFH in patients with heart attack (STEMI) receiving thrombolytic therapy with TNK, streptokinase, alteplase or reteplase
Since 1987, clot-dissolving agents such as t-PA, streptokinase and reteplase
have been the treatment of choice for patients presenting with a heart attack within six hours from the onset of symptoms.
This ongoing Phase III, international trial is evaluating the use of ReoPro in combination with a clot-busting drug called reteplase
(RETAVASE(R)) for treating heart attack patients.